{
    "name": "thalidomide",
    "comment": "Rx",
    "other_names": [
        "Thalomid"
    ],
    "classes": [
        "Antineoplastics",
        "Angiogenesis Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/thalomid-thalidomide-343211",
    "pregnancy": {
        "common": [
            "Potent teratogen; contraindicated during pregnancy (see Black Box Warnings; Contraindications, Cautions)",
            "Based on the mechanism of action, human and animal data, thalidomide can cause embryo-fetal harm when administered to pregnant female",
            "It is a powerful human teratogen, inducing a high frequency of severe and life-threatening birth defects, even after a single dose",
            "Mortality at or shortly after birth reported in ~40% of infants",
            "If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus",
            "If pregnancy occurs during treatment, discontinue the drug immediately"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "  ",
                    "Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks before initiating treatment, during therapy, during dose interruptions, and continuing for 4 weeks following therapy discontinuation",
                    "2 negative pregnancy tests must be obtained before initiating; the first test should be performed within 10-14 days and the second test within 24 hr before prescribing therapy and then weekly during the first month, then monthly thereafter in females with regular menstrual cycles or q2week in females with irregular menstrual cycles",
                    "  ",
                    "Thalidomide is present in the semen of patients; therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking thalidomide and for up to 4 weeks after discontinuing, even if they have undergone a successful vasectomy",
                    "Male patients taking thalidomide must not donate sperm"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information regarding presence of thalidomide in human milk; effects of thalidomide on breastfed infant, or effects of thalidomide on milk production",
            "Because many drugs are excreted in human milk and because of potential for adverse reactions in breastfed infants from thalidomide advise women not to breastfeed during therapy"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Embryo-fetal toxicity",
                    "description": [
                        "If taken during pregnancy, thalidomide can cause severe birth defects or embryo-fetal death",
                        "Never prescribe for females who are pregnant or who could be pregnant while taking the drug",
                        "Even a single dose (1 capsule, regardless of strength) taken by a pregnant woman during her pregnancy can cause severe birth defects",
                        "Pregnancy must be excluded before initiating treatment",
                        "Prevent pregnancy thereafter by the use of 2 reliable contraceptive methods",
                        "Prescribers must be certified with the THALOMID REMS program by enrolling and complying with the REMS requirements"
                    ]
                },
                {
                    "type": "Venous thromboembolic events ",
                    "description": [
                        "Significantly increases risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients treated for multiple myeloma; this risk increases significantly when used with standard chemotherapeutic agents, including dexamethasone",
                        "In one controlled trial, the rate of venous thromboembolic events was 22.5% in patients receiving thalidomide in combination with dexamethasone compared with 4.9% in patients receiving dexamethasone alone (P = 0.002)",
                        "Observe for signs and symptoms of thromboembolism and instruct patients to seek medical care if they develop shortness of breath, chest pain, or arm or leg swelling",
                        "Preliminary data suggest that patients who are appropriate candidates may benefit from concurrent prophylactic anticoagulation or aspirin treatment"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Pregnancy; highly teratogenic (even a single dose)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Powerful human teratogen that induces a high frequency of severe and life-threatening birth defects, even after a single dose; mortality at or shortly after birth reported in ~40% of infants; when there is no satisfactory alternant treatment, females of reproductive potential may be treated with thalidomide provided adequate precautions are taken to avoid pregnancy; only available through the Thalomid REMS program (see Black Box Warnings, Contraindications, and Pregnancy)",
                "Do not donate blood during treatment and for 4 weeks following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed thalidomide",
                "Increased risk of venous thromboembolism reported in patients with multiple myeloma (MM) treatment; the presence of underlying malignancy, and/or use of an estrogen-containing contraceptive can each increase risk of thromboembolism; it is not known if these risks of thromboembolism are additive; however, should be taken into consideration when choosing contraceptive methods (see Black Box Warnings)",
                "Ischemic heart disease (including myocardial infarction) and stroke observed",
                "Drowsiness and somnolence may occur; instruct patients to avoid situations where drowsiness may be a problem and not to take other medications that may cause drowsiness",
                "Peripheral neuropathy reported; examine patients at monthly intervals for the first 3 months of therapy and periodically thereafter; consider electrophysiological testing, consisting of measurement of sensory nerve action potential (SNAP) amplitudes at baseline and thereafter every 6 months in an effort to detect asymptomatic neuropathy; usually, treatment with this drug should only be reinitiated if neuropathy returns to baseline status",
                "Dizziness and orthostatic hypotension may occur; advise patients to sit upright for a few minutes prior to standing up from a recumbent position",
                "Thrombocytopenia, including Grade 3 or 4 occurrences, reported in association with the clinical use of thalidomide; monitor blood counts, including platelet counts; dose reduction, delay, or discontinuation may be required; monitor for signs and symptoms of bleeding including petechiae, epistaxis, and gastrointestinal bleeding, especially if concomitant medication may increase the risk of bleeding",
                "May increased HIV viral load when used in HIV-seropositive patients; clinical significance unknown, measure viral load after the first and third months of treatment and every 3 months thereafter",
                "Monitor for bradycardia and possible syncope; dose reduction or discontinuation may be required",
                "Monitor patients with a history of seizures or at risk for the development of seizures closely for clinical changes that could precipitate acute seizure activity",
                "Tumor lysis syndrome may occur; monitor patients at risk (eg, those with high tumor burden prior to treatment) and take appropriate precautions",
                "Hypersensitivity reported, including angioedema and anaphylaxis; signs and symptoms include the occurrence of erythematous macular rash, possibly associated with fever, tachycardia, and hypotension, and if severe, may necessitate therapy interruption; if the reaction recurs when dosing is resumed, discontinue thalidomide; do not resume treatment after angioedema and anaphylaxis",
                "Increased mortality was observed in 2 randomized clinical trials in patients with multiple myeloma when pembrolizumab was added to a thalidomide analog and dexamethasone; treatment with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analog plus dexamethasone is not recommended outside of controlled clinical trials"
            ],
            "specific": [
                {
                    "type": "Neutropenia",
                    "description": [
                        "Decreased white blood cell counts, including neutropenia, reported with therapy; treatment should not be initiated with an absolute neutrophil count (ANC) of <750/mm3; white blood cell count and differential should be monitored on an ongoing basis, especially in patients who maybe more prone to neutropenia, such as patients who are HIV-seropositive",
                        "If ANC decreases to below 750/mm3 while on treatment, the patient’s medication regimen should be re-evaluated and, if neutropenia persists, consideration should be given to withholding therapy if clinically appropriate"
                    ]
                },
                {
                    "type": "Severe cutaneous reactions",
                    "description": [
                        "Severe cutaneous reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) reported",
                        "DRESS may present with cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis; which can be fatal; consider interruption or discontinuation or therapy for Grade 2-3 skin rash",
                        "Discontinue therapy for Grade 4 rash, exfoliative or bullous rash, or for other severe cutaneous reactions such as SJS, TEN, or DRESS; do not resume therapy"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Avoid coadministration with other drugs that may cause additive sedation (eg, opioids, antihistamines, antipsychotics, antianxiety agents, CNS depressants)",
                        "Additive effects may occur if coadministered with drugs that cause peripheral neuropathy (eg, bortezomib, amiodarone, cisplatin, docetaxel, paclitaxel, vincristine, disulfiram, phenytoin, metronidazole, alcohol); use cautiously",
                        "Hormonal contraceptives increase risk of thromboembolism; unknown if coadministration further increases this risk",
                        "Caution if erythropoietic agents or other agents that increase risk of thromboembolism (eg, estrogen containing therapies) are coadministered in patients receiving thalidomide with dexamethasone for multiple myeloma",
                        "Drugs that interfere with hormonal contraception",
                        "Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements (eg, St. John’s Wort) with hormonal contraceptive agents may reduce the effectiveness of the contraception up to 1 month after discontinuation of these concomitant therapies",
                        "Females requiring treatment with 1 or more of these drugs must use 2 OTHER effective or highly effective methods of contraception while taking thalidomide",
                        "Bradycardia",
                        "Drugs which slow cardiac conduction may cause an additive bradycardic effect if coadministered with thalidomide and should be used with caution",
                        "Cardiovascular medications which may cause bradycardia include calcium channel blockers, beta blockers, alpha/beta-adrenergic blockers, and digoxin",
                        "Noncardiac drugs that may cause bradycardia include H2 blockers, lithium, TCAs, and neuromuscular blockers"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "acrivastine",
            "description": {
                "common": "acrivastine and thalidomide both increase  sedation. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride and thalidomide both increase  sedation. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "anakinra",
            "description": {
                "common": "anakinra increases toxicity of thalidomide by Other (see comment). Contraindicated. \nComment: Avoid concomitant use due to increased risk of infection."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine and thalidomide both increase  sedation. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and thalidomide both increase  sedation. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "avapritinib",
            "description": {
                "common": "avapritinib and thalidomide both increase  sedation. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "benzhydrocodone/acetaminophen and thalidomide both increase  sedation. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "brexpiprazole and thalidomide both increase  sedation. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clonidine",
            "description": {
                "common": "clonidine, thalidomide.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Enhanced CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deferiprone",
            "description": {
                "common": "deferiprone, thalidomide.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "thalidomide, metoclopramide intranasal.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nivolumab",
            "description": {
                "common": "thalidomide increases toxicity of nivolumab by Other (see comment). Avoid or Use Alternate Drug. \nComment: Immunosuppression diminishes therapeutic effect of nivolumab; combination also increases mortality in patients with multiple myeloma when thalidomide and dexamethasone added to therapy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olopatadine intranasal",
            "description": {
                "common": "thalidomide and olopatadine intranasal both increase  sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of thalidomide by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hr before, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod, thalidomide.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Consult cardiologist if considering treatment. Coadministration of ponesimod with drugs that decrease HR may have additive effects on decreasing HR and should generally not be initiated in these patients."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, thalidomide.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selinexor",
            "description": {
                "common": "selinexor, thalidomide. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, thalidomide.\nEither increases effects of the other by sedation. Avoid or Use Alternate Drug. Concurrent use of medications with CNS depressant effects together with thalidomide should be avoided due to the risk for additive sedative effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tocilizumab",
            "description": {
                "common": "tocilizumab, thalidomide.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive immunosuppression; risk of serious infection."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vedolizumab",
            "description": {
                "common": "vedolizumab and thalidomide both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid coadministration of vedolizumab with TNF blockers because of the potential for increased risk of infections"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "thalidomide increases effects of amobarbital by unspecified interaction mechanism. Use Caution/Monitor. Increased sedative effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexanolone",
            "description": {
                "common": "brexanolone, thalidomide.\nEither increases toxicity of the other by sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butabarbital",
            "description": {
                "common": "thalidomide increases effects of butabarbital by unspecified interaction mechanism. Use Caution/Monitor. Increased sedative effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butalbital",
            "description": {
                "common": "thalidomide increases effects of butalbital by unspecified interaction mechanism. Use Caution/Monitor. Increased sedative effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate, thalidomide.\nEither increases effects of the other by sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "thalidomide increases effects of chlorpromazine by unspecified interaction mechanism. Use Caution/Monitor. Increased sedative effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "thalidomide decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daridorexant",
            "description": {
                "common": "thalidomide and daridorexant both increase  sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and thalidomide both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difelikefalin",
            "description": {
                "common": "difelikefalin and thalidomide both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esketamine intranasal",
            "description": {
                "common": "esketamine intranasal, thalidomide.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethanol",
            "description": {
                "common": "thalidomide increases effects of ethanol by unspecified interaction mechanism. Use Caution/Monitor. Increased sedative effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "thalidomide increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ganaxolone",
            "description": {
                "common": "thalidomide and ganaxolone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "lasmiditan, thalidomide.\nEither increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "lemborexant will increase the level or effect of thalidomide by  sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone, thalidomide.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "mechlorethamine, thalidomide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration with mechlorethamine may increase the risk of immunosuppression and myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "midazolam intranasal, thalidomide.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, thalidomide.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "thalidomide increases effects of pentobarbital by unspecified interaction mechanism. Use Caution/Monitor. Increased sedative effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "thalidomide increases effects of phenobarbital by unspecified interaction mechanism. Use Caution/Monitor. Increased sedative effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "thalidomide increases effects of primidone by unspecified interaction mechanism. Use Caution/Monitor. Increased sedative effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "thalidomide increases effects of secobarbital by unspecified interaction mechanism. Use Caution/Monitor. Increased sedative effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and thalidomide both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sipuleucel-T",
            "description": {
                "common": "thalidomide decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, thalidomide.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, thalidomide.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "benazepril",
            "description": {
                "common": "thalidomide, benazepril.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May increase risk of hypotension."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "captopril",
            "description": {
                "common": "thalidomide, captopril.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May increase risk of hypotension."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "food",
            "description": {
                "common": "food decreases levels of thalidomide by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Esp. high fat foods."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "shark cartilage",
            "description": {
                "common": "thalidomide, shark cartilage.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Enhanced anti angiogenesis (theoretical interaction)."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Fatigue",
            "percent": "21-79"
        },
        {
            "name": "Hypocalcemia",
            "percent": "72"
        },
        {
            "name": "Edema",
            "percent": "13-56"
        },
        {
            "name": "Constipation",
            "percent": "50-55"
        },
        {
            "name": "Neuropathy",
            "percent": "54"
        },
        {
            "name": "sensory",
            "percent": "42"
        },
        {
            "name": "Dyspnea",
            "percent": "40"
        },
        {
            "name": "Muscle weakness",
            "percent": "35"
        },
        {
            "name": "Leukocytes decreased",
            "percent": "34"
        },
        {
            "name": "Peripheral edema",
            "percent": "31"
        },
        {
            "name": "Neutrophils decreased",
            "percent": "30"
        },
        {
            "name": "Rash",
            "percent": "28"
        },
        {
            "name": "desquamation",
            "percent": "28"
        },
        {
            "name": "Confusion",
            "percent": "13-28"
        },
        {
            "name": "Anorexia",
            "percent": "26"
        },
        {
            "name": "Nausea",
            "percent": "26"
        },
        {
            "name": "Anxiety",
            "percent": "24"
        },
        {
            "name": "agitation",
            "percent": "24"
        },
        {
            "name": "Tremor",
            "percent": "23"
        },
        {
            "name": "Fever",
            "percent": "22"
        },
        {
            "name": "Asthenia",
            "percent": "22"
        },
        {
            "name": "Weight loss",
            "percent": "22"
        },
        {
            "name": "Weight gain",
            "percent": "21"
        },
        {
            "name": "Thrombosis",
            "percent": "20-23"
        },
        {
            "name": "embolism",
            "percent": "17"
        },
        {
            "name": "Neuropathy",
            "percent": "16"
        },
        {
            "name": "motor",
            "percent": "15"
        },
        {
            "name": "Dry skin",
            "percent": "15"
        },
        {
            "name": "Dizziness",
            "percent": "14"
        },
        {
            "name": "lightheadedness",
            "percent": "13"
        },
        {
            "name": "Myalgia",
            "percent": "13"
        },
        {
            "name": "Depressed level of consciousness",
            "percent": "12"
        },
        {
            "name": "Pneumonia",
            "percent": "12"
        },
        {
            "name": "Hyperglycemia",
            "percent": "12"
        },
        {
            "name": "Bilirubin",
            "percent": "11"
        },
        {
            "name": "Arthralgia",
            "percent": "36-38"
        },
        {
            "name": "Deep vein thrombosis",
            "percent": "21-25"
        },
        {
            "name": "Dry mouth",
            "percent": "17-25"
        },
        {
            "name": "Paresthesia",
            "percent": "17-22"
        },
        {
            "name": "Anxiety",
            "percent": "6-22"
        },
        {
            "name": "Dyspepsia",
            "percent": "13-19"
        },
        {
            "name": "Somnolence",
            "percent": "11-19"
        },
        {
            "name": "Rash",
            "percent": "4-19"
        },
        {
            "name": "Leukopenia",
            "percent": "4-19"
        },
        {
            "name": "Fever",
            "percent": "6-16"
        },
        {
            "name": "Asthenia",
            "percent": "13"
        },
        {
            "name": "Headache",
            "percent": "6-13"
        },
        {
            "name": "Diarrhea",
            "percent": "6-13"
        },
        {
            "name": "Dizziness",
            "percent": "4-13"
        },
        {
            "name": "Maculopapular rash",
            "percent": "3-13"
        },
        {
            "name": "Paresthesia",
            "percent": "11"
        },
        {
            "name": "Sweating",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Lymphadenopathy",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "SGOT increased",
            "percent": null
        },
        {
            "name": "Hematuria",
            "percent": null
        },
        {
            "name": "Blood and lymphatic",
            "percent": null
        },
        {
            "name": "Decreased white blood cell counts including febrile neutropenia",
            "percent": null
        },
        {
            "name": "changes in prothrombin time",
            "percent": null
        },
        {
            "name": "pancytopenia",
            "percent": null
        },
        {
            "name": "chronic myelogenous leukemia",
            "percent": null
        },
        {
            "name": "nodular sclerosing Hodgkin disease",
            "percent": null
        },
        {
            "name": "erythroleukemia",
            "percent": null
        },
        {
            "name": "lymphedema",
            "percent": null
        },
        {
            "name": "and lymphopenia",
            "percent": null
        },
        {
            "name": "Body as a whole",
            "percent": null
        },
        {
            "name": "Hangover effect",
            "percent": null
        },
        {
            "name": "Cardiovascular System",
            "percent": null
        },
        {
            "name": "Sick sinus syndrome",
            "percent": null
        },
        {
            "name": "EKG abnormalities",
            "percent": null
        },
        {
            "name": "pulmonary hypertension",
            "percent": null
        },
        {
            "name": "Digestive system",
            "percent": null
        },
        {
            "name": "Intestinal perforation",
            "percent": null
        },
        {
            "name": "gastrointestinal perforations",
            "percent": null
        },
        {
            "name": "bile duct obstruction",
            "percent": null
        },
        {
            "name": "stomach ulcer",
            "percent": null
        },
        {
            "name": "aphthous",
            "percent": null
        },
        {
            "name": "stomatitis",
            "percent": null
        },
        {
            "name": "Ear and labyrinthine disorders",
            "percent": null
        },
        {
            "name": "Hearing impairment",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Hypersensitivity including anaphylaxis",
            "percent": null
        },
        {
            "name": "solid organ transplant rejection",
            "percent": null
        },
        {
            "name": "Infections and infestations",
            "percent": null
        },
        {
            "name": "Severe infections",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "fatal sepsis including septic shock",
            "percent": null
        },
        {
            "name": "and viral infections",
            "percent": null
        },
        {
            "name": "including varicella zoster virus",
            "percent": null
        },
        {
            "name": "cytomegalovirus",
            "percent": null
        },
        {
            "name": "and hepatitis B virus reactivation",
            "percent": null
        },
        {
            "name": "progressive and multifocal leukoencephalopathy",
            "percent": null
        },
        {
            "name": "Metabolic and endocrine",
            "percent": null
        },
        {
            "name": "Electrolyte imbalance including hypercalcemia",
            "percent": null
        },
        {
            "name": "hyponatremia and hypomagnesemia",
            "percent": null
        },
        {
            "name": "hypothyroidism",
            "percent": null
        },
        {
            "name": "increased alkaline phosphatase",
            "percent": null
        },
        {
            "name": "tumor lysis syndrome",
            "percent": null
        },
        {
            "name": "myxedema",
            "percent": null
        },
        {
            "name": "Nervous system",
            "percent": null
        },
        {
            "name": "Changes in mental status or mood including suicide attempts",
            "percent": null
        },
        {
            "name": "disturbances in consciousness including lethargy",
            "percent": null
        },
        {
            "name": "loss of consciousness or stupor",
            "percent": null
        },
        {
            "name": "seizures including grand mal convulsions and status epilepticus",
            "percent": null
        },
        {
            "name": "Parkinson disease",
            "percent": null
        },
        {
            "name": "stroke",
            "percent": null
        },
        {
            "name": "carpal tunnel",
            "percent": null
        },
        {
            "name": "Raynaud syndrome",
            "percent": null
        },
        {
            "name": "migraine",
            "percent": null
        },
        {
            "name": "foot drop",
            "percent": null
        },
        {
            "name": "Renal and urinary disorders",
            "percent": null
        },
        {
            "name": "Renal failure",
            "percent": null
        },
        {
            "name": "acute renal failure",
            "percent": null
        },
        {
            "name": "oliguria",
            "percent": null
        },
        {
            "name": "enuresis",
            "percent": null
        },
        {
            "name": "Reproductive system and breast disorders",
            "percent": null
        },
        {
            "name": "amenorrhea",
            "percent": null
        },
        {
            "name": "sexual dysfunction",
            "percent": null
        },
        {
            "name": "galactorrhea",
            "percent": null
        },
        {
            "name": "gynecomastia",
            "percent": null
        },
        {
            "name": "metrorrhagia",
            "percent": null
        },
        {
            "name": "Respiratory system",
            "percent": null
        },
        {
            "name": "Pleural effusion",
            "percent": null
        },
        {
            "name": "interstitial lung disease",
            "percent": null
        },
        {
            "name": "Skin and appendages",
            "percent": null
        },
        {
            "name": "Erythema multiforme",
            "percent": null
        },
        {
            "name": "erythema nodosum",
            "percent": null
        },
        {
            "name": "toxic epidermal necrolysis",
            "percent": null
        },
        {
            "name": "TEN",
            "percent": null
        },
        {
            "name": "drug reaction with eosinophilia and systemic symptoms",
            "percent": null
        },
        {
            "name": "DRESS",
            "percent": null
        },
        {
            "name": "purpura",
            "percent": null
        },
        {
            "name": "petechiae",
            "percent": null
        },
        {
            "name": "Special senses",
            "percent": null
        },
        {
            "name": "Diplopia",
            "percent": null
        },
        {
            "name": "nystagmus",
            "percent": null
        }
    ]
}